Pattern Recognition Receptors: Significance of Expression in the Liver.


Journal

Archivum immunologiae et therapiae experimentalis
ISSN: 1661-4917
Titre abrégé: Arch Immunol Ther Exp (Warsz)
Pays: Switzerland
ID NLM: 0114365

Informations de publication

Date de publication:
17 Sep 2020
Historique:
received: 31 12 2019
accepted: 02 09 2020
entrez: 18 9 2020
pubmed: 19 9 2020
medline: 29 6 2021
Statut: epublish

Résumé

Pattern recognition receptors (PRRs) are a pivotal part of the immune system. They are distributed in almost every site of higher organisms, able to recognize foreign pathogens or unwanted remnants of metabolism and mount innate immune response. Moreover, PRRs create bridging signaling to initiate adaptive immunity. The liver being the largest organ of the body, exposed to myriads of foreign substances often being immunogenic, is well equipped with PRRs. They act as sentinels of the organ, both in health and disease. In viral hepatitis C at least two of them, RIG-1 and TLR3 sense HCV, induce protective interferon production and create proinflammatory status. The hepatitis B virus is apparently invisible to PRRs, which has recently been denied. Besides, they are active in the course of infection. In liver injury and hepatic fibrogenesis Toll-like receptors (TLRs), predominantly TLR4, TLR3 and TLR9 are associated with gut microflora-related products and DNA from dying hepatocytes, lead to the activation of hepatic stellate cells. The latter initiate production of fibrillar collagens, the main agents forming hepatic fibrosis. Tumor cells of primary liver cancer also express PRRs, mainly TLRs. In concert with non-resolving liver inflammation, they are considered pivotal factors leading to carcinogenesis.

Identifiants

pubmed: 32944845
doi: 10.1007/s00005-020-00595-1
pii: 10.1007/s00005-020-00595-1
pmc: PMC7498499
doi:

Substances chimiques

Receptors, Pattern Recognition 0
Toll-Like Receptors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

29

Subventions

Organisme : Narodowe Centrum Nauki
ID : 2016/23/B/NZ6/01497

Références

Int J Cancer. 2018 Jan 1;142(1):81-91
pubmed: 28875549
J Exp Med. 2005 Oct 17;202(8):1131-9
pubmed: 16230478
Semin Liver Dis. 2017 May;37(2):119-127
pubmed: 28564720
J Innate Immun. 2018;10(4):339-348
pubmed: 29975940
World J Gastroenterol. 2006 Feb 28;12(8):1198-204
pubmed: 16534871
Gastroenterology. 2006 Feb;130(2):435-52
pubmed: 16472598
Gastroenterology. 2008 May;134(6):1655-69
pubmed: 18471545
Hepatology. 2007 Nov;46(5):1509-18
pubmed: 17705260
Vaccines (Basel). 2018 Feb 28;6(1):
pubmed: 29495555
Zhonghua Gan Zang Bing Za Zhi. 2019 Apr 20;27(4):286-290
pubmed: 31082340
Autoimmun Rev. 2008 Jan;7(3):204-8
pubmed: 18190879
Viral Immunol. 2018 Oct;31(8):559-567
pubmed: 30067145
J Virol. 2009 Jan;83(2):847-58
pubmed: 18971270
Immunol Cell Biol. 2007 Aug-Sep;85(6):420-4
pubmed: 17637696
Gastroenterology. 2012 Nov;143(5):1330-1340.e1
pubmed: 22841787
Mol Immunol. 2018 Jul;99:171-181
pubmed: 29793131
J Clin Invest. 2006 Sep;116(9):2456-63
pubmed: 16955143
Ann Surg. 2020 May;271(5):922-931
pubmed: 30480558
J Hepatol. 2019 Oct;71(4):763-772
pubmed: 31220470
Mol Med Rep. 2019 Jan;19(1):3-14
pubmed: 30483776
Int J Oncol. 2010 Oct;37(4):805-14
pubmed: 20811701
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2992-7
pubmed: 15710891
J Viral Hepat. 2009 May;16(5):315-24
pubmed: 19243499
World J Hepatol. 2016 Nov 18;8(32):1354-1369
pubmed: 27917262
Virol J. 2012 Jun 22;9:126
pubmed: 22726246
J Gen Virol. 2010 Aug;91(Pt 8):2080-2090
pubmed: 20375222
Hepatology. 2020 Jan 11;:
pubmed: 31925967
Gastroenterol Hepatol Bed Bench. 2017 Fall;10(4):278-283
pubmed: 29379592
Gastroenterology. 2004 Nov;127(5):1513-24
pubmed: 15521019
Fibrogenesis Tissue Repair. 2010 Oct 21;3:21
pubmed: 20964825
Arch Virol. 2018 Sep;163(9):2433-2442
pubmed: 29860675
J Immunol. 2013 Nov 1;191(9):4473-4
pubmed: 24141853
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:38-42
pubmed: 23855294
Trends Immunol. 2018 Sep;39(9):712-723
pubmed: 29843959
Gastroenterology. 2018 May;154(6):1778-1790
pubmed: 29408639
Hepat Mon. 2014 Apr 07;14(4):e16421
pubmed: 24748896
Egypt J Immunol. 2017 Jun;24(2):173-185
pubmed: 29528590
Viral Immunol. 2016 Nov;29(9):496-501
pubmed: 27750030
Cell. 2006 Feb 24;124(4):783-801
pubmed: 16497588
Adv Immunol. 2011;109:87-124
pubmed: 21569913
Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):451-458
pubmed: 30396012
Arch Immunol Ther Exp (Warsz). 2019 Jun;67(3):133-141
pubmed: 30976817
Nat Med. 2007 Nov;13(11):1324-32
pubmed: 17952090
Gastroenterol Res Pract. 2010;2010:
pubmed: 20706677
J Viral Hepat. 2010 Feb 1;17(2):130-8
pubmed: 19674283
J Virol. 2009 Oct;83(19):9824-34
pubmed: 19625408
Cell. 1996 Sep 20;86(6):973-83
pubmed: 8808632
Physiol Rev. 2015 Jan;95(1):149-78
pubmed: 25540141
Immunol Invest. 2019 Apr;48(3):321-332
pubmed: 30321082
Zhonghua Gan Zang Bing Za Zhi. 2017 Dec 20;25(12):908-913
pubmed: 29325291
Int Immunopharmacol. 2019 May;70:147-155
pubmed: 30802677
J Clin Invest. 2019 Apr 1;129(4):1803
pubmed: 30932913
Saudi J Biol Sci. 2019 Feb;26(2):270-280
pubmed: 31485165
Arch Immunol Ther Exp (Warsz). 2010 Aug;58(4):295-302
pubmed: 20533094
J Clin Invest. 2016 Mar 1;126(3):859-64
pubmed: 26808498
NPJ Precis Oncol. 2018 Feb 23;2(1):6
pubmed: 29872724
Cancer Cell. 2012 Apr 17;21(4):504-16
pubmed: 22516259
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:93-8
pubmed: 23855302
Gastroenterology. 2018 May;154(6):1764-1777.e7
pubmed: 29378197
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7431-6
pubmed: 20231459
Hepatology. 2003 May;37(5):1043-55
pubmed: 12717385
Mol Metab. 2018 Aug;14:121-129
pubmed: 29884546
Clin Res Hepatol Gastroenterol. 2018 Apr;42(2):139-144
pubmed: 29276096
Biochem Biophys Res Commun. 2008 Nov 14;376(2):271-6
pubmed: 18760996
Genet Mol Res. 2016 Jul 14;15(2):
pubmed: 27420991

Auteurs

Jan Żeromski (J)

Chair of Pathomorphology and Clinical Immunology, Karol Marcinkowski University of Medical Sciences, Poznan, Poland. jzeromski@ump.edu.pl.

Agata Kierepa (A)

Chair and Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.

Bartosz Brzezicha (B)

Chair of Pathomorphology and Clinical Immunology, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.

Arleta Kowala-Piaskowska (A)

Chair and Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.

Iwona Mozer-Lisewska (I)

Chair and Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH